Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Smruthi Organics Limited (SMRUTHIORG.BO)
Solapur, IN
Smruthi Organics Ltd. primarily focuses on the production and commercialization of bulk pharmaceutical ingredients and their chemical intermediates. The company's product range includes a variety of compounds such as amlodipine besilate, amisulpride, carbidopa, ciprofloxacin, diloxanide furoate, fenofibrate, metformin hydrochloride, norfloxacin, pefloxacin, telmisartan, amlodipine base, and phthaloyl amlodipine. This enterprise was established on July 11, 1989, by Purushotham Mallayya Eaga and is based in Solapur, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.95% | -4.33% | -4.17% | +2.68% | -10.92% | -1.63% | -12.61% | -23.87% | -52.77% | +183.25% | +58.56% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Pharmaceuticals: +7.8%-19.1% Q1'26: -23.6% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%-3.9% Q1'26: -52.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+14.2% ★ Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+6.6% Q1'26: +7.0% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+6.2% ★ Q1'26: +6.3% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.0% Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.64× Q1'26: 0.55× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|
| Revenue |
1.32B
1.32B – 1.32B
|
1.32B
1.32B – 1.32B
+0.0% YoY
|
1.50B
1.50B – 1.50B
+13.6% YoY
|
| EBITDA |
140.08M
140.08M – 140.08M
|
140.08M
140.08M – 140.08M
+0.0% YoY
|
159.19M
159.19M – 159.19M
+13.6% YoY
|
| EBIT |
83.96M
83.96M – 83.96M
|
83.96M
83.96M – 83.96M
+0.0% YoY
|
95.41M
95.41M – 95.41M
+13.6% YoY
|
| Net Income |
45.83M
45.83M – 45.83M
|
45.83M
45.83M – 45.83M
+0.0% YoY
|
81.34M
81.34M – 81.34M
+77.5% YoY
|
| SGA |
82.26M
82.26M – 82.26M
|
82.26M
82.26M – 82.26M
+0.0% YoY
|
93.47M
93.47M – 93.47M
+13.6% YoY
|
| EPS |
4.00
4.00 – 4.00
|
4.00
4.00 – 4.00
+0.0% YoY
|
7.10
7.10 – 7.10
+77.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Purushotham Malaiah Eaga | Founder, Executive Chairman & MD | 21M | male |
| Swapnil Purushotham Eaga | Joint MD, Chief Financial Officer & Executive Director | 14M | male |
| Urvashi Dravendta Khanna | Compliance Officer & Company Secretary | 481.6K | female |
| Vijay Changale | Senior Manager of Accounts & Finance | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SMRUTHIORG.BO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
